These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9013820)

  • 1. Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia.
    Nakai A; Nishikata M; Uchida T; Ichikawa M; Matsuyama K
    Biol Pharm Bull; 1997 Jan; 20(1):104-6. PubMed ID: 9013820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method.
    Matsuyama K; Nakagawa K; Nakai A; Konishi Y; Nishikata M; Tanaka H; Uchida T
    Biol Pharm Bull; 2002 Mar; 25(3):346-50. PubMed ID: 11913531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
    Tal A; Rajeshawari M; Isley W
    South Med J; 1997 May; 90(5):546-7. PubMed ID: 9160078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
    Feher MD; Foxton J; Banks D; Lant AF; Wray R
    Br Heart J; 1995 Jul; 74(1):14-7. PubMed ID: 7662446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
    Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; Vyas KP; Kari PH; MacDonald JS
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1225-35. PubMed ID: 1904494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?].
    Galiana J; Marchán E; Montés I; Pato S
    Rev Clin Esp; 1995 Sep; 195(9):620-2. PubMed ID: 7481005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering agents and myopathy.
    Wortmann RL
    Curr Opin Rheumatol; 2002 Nov; 14(6):643-7. PubMed ID: 12410084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myopathy and rhabdomyolysis with lipid-lowering drugs.
    Hodel C
    Toxicol Lett; 2002 Mar; 128(1-3):159-68. PubMed ID: 11869826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report].
    Kedzia A; Krysiak R; Madej A; Okopień B
    Pol Arch Med Wewn; 2007 Oct; 117(10):473-6. PubMed ID: 18320790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral simvastatin as an antilipemic therapy: effect on creatine kinase in hypercholesterolemic subjects.
    Assawawitoontip S; Wiwanitkit V
    Clin Lab; 2003; 49(3-4):147-50. PubMed ID: 12705697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
    Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
    Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
    [No Abstract]   [Full Text] [Related]  

  • 12. Morphometry of abnormal peroxisomes induced by withdrawal of bezafibrate, a hypolipidemic drug in male rat hepatocytes.
    Kondo K; Makita T
    J Vet Med Sci; 1997 Apr; 59(4):297-9. PubMed ID: 9152941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.
    Horn M
    Arch Dermatol; 1996 Oct; 132(10):1254. PubMed ID: 8859048
    [No Abstract]   [Full Text] [Related]  

  • 14. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
    Pierce LR; Wysowski DK; Gross TP
    JAMA; 1990 Jul; 264(1):71-5. PubMed ID: 2355431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Bortolini M; Salko T; Freudenreich MO; Isaacsohn JL; Troendle AJ; Gonasun L
    Am J Cardiol; 2003 Jan; 91(2):238-40. PubMed ID: 12521642
    [No Abstract]   [Full Text] [Related]  

  • 16. Lovastatin and myopathy.
    Tobert JA
    Am J Med; 1994 Mar; 96(3):300-1. PubMed ID: 8154521
    [No Abstract]   [Full Text] [Related]  

  • 17. Retention of sarcoplasmic calcium inhibits development of the phencyclidine-restraint experimental myopathy.
    Ross-Canada J; Chizzonite RA; Meltzer HY
    Exp Neurol; 1983 Jan; 79(1):1-10. PubMed ID: 6822247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Statins and muscular adverse effects].
    Schjøtt J
    Tidsskr Nor Laegeforen; 2000 Dec; 120(30):3729-31. PubMed ID: 11215947
    [No Abstract]   [Full Text] [Related]  

  • 19. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
    Illingworth DR; Erkelens DW; Keller U; Thompson GR; Tikkanen MJ
    Lancet; 1994 Jun; 343(8912):1554-5. PubMed ID: 7911877
    [No Abstract]   [Full Text] [Related]  

  • 20. Pravastatin and simvastatin for hypercholesterolemia.
    Med Lett Drugs Ther; 1991 Mar; 33(839):18-20. PubMed ID: 1899899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.